

Elizabeth A Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10667781/publications.pdf>

Version: 2024-02-01

70
papers

4,054
citations

109137

35
h-index

123241

61
g-index

70
all docs

70
docs citations

70
times ranked

5842
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. <i>Nature Neuroscience</i> , 2010, 13, 1113-1119.	7.1	534
2	The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 15564-15569.	3.3	271
3	Molecular profiles of schizophrenia in the CNS at different stages of illness. <i>Brain Research</i> , 2008, 1239, 235-248.	1.1	178
4	Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. <i>Journal of Neuroscience Research</i> , 1997, 50, 1047-1052.	1.3	162
5	Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. <i>Neurobiology of Disease</i> , 2012, 46, 351-361.	2.1	157
6	Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. <i>Human Molecular Genetics</i> , 2012, 21, 5280-5293.	1.4	128
7	Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. <i>Genome Research</i> , 2010, 20, 403-412.	2.4	127
8	Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. <i>Journal of Neurochemistry</i> , 2006, 96, 743-757.	2.1	125
9	Glycolipid and ganglioside metabolism imbalances in Huntington's disease. <i>Neurobiology of Disease</i> , 2007, 27, 265-277.	2.1	120
10	HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E56-64.	3.3	95
11	The 5-HT _{2A} serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: A mechanism for neuronal suppression of reactive astrocytes. , 1996, 17, 317-326.		87
12	Evidence for disruption of sphingolipid metabolism in schizophrenia. <i>Journal of Neuroscience Research</i> , 2009, 87, 278-288.	1.3	85
13	Epigenetic changes at gene promoters in response to immune activation in utero. <i>Brain, Behavior, and Immunity</i> , 2013, 30, 168-175.	2.0	78
14	RGS9: A regulator of G-protein signalling with specific expression in rat and mouse striatum. <i>Journal of Neuroscience Research</i> , 1998, 52, 118-124.	1.3	76
15	Gene Expression Profiling in Brodmann's Area 46 from Subjects with Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 308-320.	1.3	74
16	The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice. <i>PLoS ONE</i> , 2016, 11, e0152498.	1.1	73
17	Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease. <i>Neurobiology of Disease</i> , 2008, 31, 298-308.	2.1	63
18	Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. <i>Neurobiology of Disease</i> , 2011, 42, 459-467.	2.1	63

#	ARTICLE	IF	CITATIONS
19	Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. <i>Journal of Neurochemistry</i> , 2008, 76, 789-796.	2.1	60
20	A role of apolipoprotein D in triglyceride metabolism. <i>Journal of Lipid Research</i> , 2010, 51, 1298-1311.	2.0	59
21	In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. <i>Human Molecular Genetics</i> , 2011, 20, 1049-1060.	1.4	56
22	Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. <i>Human Molecular Genetics</i> , 2012, 21, 3097-3111.	1.4	55
23	Complex neuroprotective and neurotoxic effects of histone deacetylases. <i>Journal of Neurochemistry</i> , 2018, 145, 96-110.	2.1	55
24	Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine ₇ receptors. <i>Biochemical Pharmacology</i> , 1999, 58, 1807-1813.	2.0	54
25	Striatal specificity of gene expression dysregulation in Huntington's disease. <i>Journal of Neuroscience Research</i> , 2006, 84, 1151-1164.	1.3	53
26	Genome-Wide Identification of Bcl11b Gene Targets Reveals Role in Brain-Derived Neurotrophic Factor Signaling. <i>PLoS ONE</i> , 2011, 6, e23691.	1.1	53
27	Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain. <i>Journal of Neuroscience Research</i> , 2007, 85, 757-765.	1.3	52
28	Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease. <i>Biological Psychiatry</i> , 2003, 54, 136-141.	0.7	51
29	Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors. <i>Molecular Neurobiology</i> , 2009, 40, 33-45.	1.9	50
30	Increased cortical expression of the zinc transporter SLC39A12 suggests a breakdown in zinc cellular homeostasis as part of the pathophysiology of schizophrenia. <i>NPJ Schizophrenia</i> , 2016, 2, 16002.	2.0	47
31	Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. <i>Biological Psychiatry</i> , 2003, 54, 616-622.	0.7	41
32	Normal human aging and early-stage schizophrenia share common molecular profiles. <i>Aging Cell</i> , 2009, 8, 339-342.	3.0	41
33	Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington's Disease Patients. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 335.	1.4	41
34	Involvement of the M2 muscarinic receptor in contractions of the guinea pig trachea, guinea pig esophagus, and rat fundus. <i>Biochemical Pharmacology</i> , 1996, 51, 779-788.	2.0	40
35	The Endogenous Lipid Oleamide Activates Serotonin 5-HT ₇ Neurons in Mouse Thalamus and Hypothalamus. <i>Journal of Neurochemistry</i> , 2002, 72, 2370-2378.	2.1	40
36	Functional role of M2 muscarinic receptors in the guinea pig ileum. <i>Life Sciences</i> , 1995, 56, 965-971.	2.0	37

#	ARTICLE	IF	CITATIONS
37	Cerebellar lipid differences between R6/1 transgenic mice and humans with Huntington's disease. <i>Journal of Neurochemistry</i> , 2010, 115, 748-758.	2.1	36
38	Molecular Profiling of Antipsychotic Drug Function: Convergent Mechanisms in the Pathology and Treatment of Psychiatric Disorders. <i>Molecular Neurobiology</i> , 2006, 34, 109-128.	1.9	35
39	Apolipoprotein D modulates arachidonic acid signaling in cultured cells: implications for psychiatric disorders. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2003, 69, 421-427.	1.0	34
40	Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. <i>Psychiatry Research</i> , 2012, 196, 201-206.	1.7	34
41	Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors. <i>Pharmaceuticals</i> , 2014, 7, 634-661.	1.7	34
42	DNA methylation in Huntington's disease: Implications for transgenerational effects. <i>Neuroscience Letters</i> , 2016, 625, 34-39.	1.0	33
43	The Neurobiology of Apolipoproteins in Psychiatric Disorders. <i>Molecular Neurobiology</i> , 2002, 26, 369-388.	1.9	32
44	Phospholipase C Beta 1 Expression in the Dorsolateral Prefrontal Cortex from Patients with Schizophrenia at Different Stages of Illness. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 140-147.	1.3	29
45	Levels of Interleukin-6 in Saliva, but Not Plasma, Correlate with Clinical Metrics in Huntington's Disease Patients and Healthy Control Subjects. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6363.	1.8	27
46	Evolutionarily Distinct Classes of S27 Ribosomal Proteins with Differential mRNA Expression in Rat Hypothalamus. <i>Journal of Neurochemistry</i> , 2002, 74, 2259-2267.	2.1	26
47	Histone Posttranslational Modifications in Schizophrenia. <i>Advances in Experimental Medicine and Biology</i> , 2017, 978, 237-254.	0.8	26
48	Apolipoprotein D mRNA expression is elevated in PDAPP transgenic mice. <i>Journal of Neurochemistry</i> , 2008, 79, 1059-1064.	2.1	25
49	Salivary levels of total huntingtin are elevated in Huntington's disease patients. <i>Scientific Reports</i> , 2018, 8, 7371.	1.6	25
50	Pertussis toxin treatment prevents 5-HT5a receptor-mediated inhibition of cyclic AMP accumulation in rat C6 glioma cells. <i>Journal of Neuroscience Research</i> , 2000, 61, 75-81.	1.3	24
51	Sphingolipid abnormalities in psychiatric disorders: a missing link in pathology?. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1797.	3.0	24
52	Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D. <i>Schizophrenia Research</i> , 2007, 89, 147-153.	1.1	23
53	Novel Isoform of Insulin Receptor Substrate p53/p58 Is Generated by Alternative Splicing in the CRIB/SH3-binding Region. <i>Journal of Biological Chemistry</i> , 2002, 277, 24728-24734.	1.6	21
54	Egr-1 Induces DARPP-32 Expression in Striatal Medium Spiny Neurons via a Conserved Intragenic Element. <i>Journal of Neuroscience</i> , 2012, 32, 6808-6818.	1.7	21

#	ARTICLE	IF	CITATIONS
55	Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. <i>Schizophrenia Research</i> , 2005, 72, 259-266.	1.1	19
56	Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 32-38.	1.1	19
57	Insulin receptor substrate protein p53 localization in rats suggests mechanism for specific polyglutamine neurodegeneration. <i>Neuroscience Letters</i> , 2001, 309, 145-148.	1.0	17
58	Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. <i>Brain Research</i> , 2017, 1673, 102-110.	1.1	16
59	Saliva testing as a means to monitor therapeutic lithium levels in patients with psychiatric disorders: Identification of clinical and environmental covariates, and their incorporation into a prediction model. <i>Bipolar Disorders</i> , 2021, 23, 679-688.	1.1	14
60	Regulator of G-Protein Signalling 4 Expression is Not Altered in the Prefrontal Cortex in Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008, 42, 740-745.	1.3	12
61	Low density lipoprotein receptor-related protein and apolipoprotein E expression is altered in schizophrenia. <i>Frontiers in Psychiatry</i> , 2010, 1, 19.	1.3	12
62	Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2014, 3, 311-316.	0.9	12
63	Behavioral and transcriptome alterations in male and female mice with postnatal deletion of TrkB in dorsal striatal medium spiny neurons. <i>Molecular Neurodegeneration</i> , 2013, 8, 47.	4.4	11
64	Reducing Mcl-1 gene dosage induces dopaminergic neuronal loss and motor impairments in Park2 knockout mice. <i>Communications Biology</i> , 2019, 2, 125.	2.0	11
65	Associations between prognostic index scores and plasma neurofilament light in Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 25-28.	1.1	6
66	Salivary S100 calcium-binding protein beta (S100B) and neurofilament light (NfL) after acute exposure to repeated head impacts in collegiate water polo players. <i>Scientific Reports</i> , 2022, 12, 3439.	1.6	5
67	The Role of Histone Deacetylase Inhibition in the Accumulation and Stability of Disease-Related Proteins. , 2017, , 159-179.		3
68	Epigenetic mechanisms in Huntington's disease. , 2019, , 73-95.		3
69	Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. , 1997, 50, 1047.		3
70	Changes in Gene Expression in Subjects with Schizophrenia Associated with Disease Progression. , 2011, , 237-251.		1